Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by INVENTIVA
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
July 31, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
July 25, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces a €20.1 million issuance of royalty certificates
July 18, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
July 05, 2024
From
INVENTIVA
Via
GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
June 21, 2024
From
INVENTIVA
Via
GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
June 21, 2024
From
INVENTIVA
Via
GlobeNewswire
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
May 30, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
May 22, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
May 21, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
May 16, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
May 13, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
April 03, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the nomination of Andre Turenne as Director
March 28, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva reports its 2023 full-year results
March 27, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
March 22, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
March 18, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
March 13, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
March 07, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
February 15, 2024
From
INVENTIVA
Via
GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
January 24, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
January 10, 2024
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
December 20, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
December 04, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva reports 2023 Third Quarter Financial Information¹
November 21, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
November 06, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva reports its 2023 first-half financial results and provides a corporate update
September 28, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 20, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
August 31, 2023
From
INVENTIVA
Via
GlobeNewswire
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
July 27, 2023
From
INVENTIVA
Via
GlobeNewswire
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
July 27, 2023
From
INVENTIVA
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.